October 14, 2008
Abraxis BioScience Names Edward Geehr, M.D., Executive Vice President of Operations
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that Edward C. Geehr, M.D., has joined the company as Executive Vice President of Operations. Dr. Geehr, 59, will report to Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer of Abraxis BioScience.
In this newly created position, Dr. Geehr will be responsible for the commercial, manufacturing and marketing operations of Abraxis. "Edward Geehr's extensive operational knowledge gained from serving in key management roles, and his experience guiding companies during periods of rapid growth, will support the expansion of Abraxis as we continue to broaden the company's commercial operations," said Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer of Abraxis BioScience. "Ed's career combines both entrepreneurial and executive experience in the healthcare industry, an important foundation that will serve Abraxis BioScience. Ed is a welcome addition to our management team as we continue to launch ABRAXANE(R) in countries around the world, enhance our robust clinical program and invest in drug discovery both internally and through industry and academic partnerships."
Dr. Geehr also was associate clinical professor of medicine and surgery at the University of California, San Francisco, and chief of emergency medicine at San Francisco General Hospital. Additionally, he was professor and chairman of emergency medicine and general director of hospital operations at Albany Medical College. He received his B.A. from Yale University and M.D. from Duke University with a residency in emergency medicine at the University of California, Los Angeles.
Dr. Geehr serves as a member of the board of directors of MedManage Systems, an online pharmaceutical samples company based in Bothell, Washington, and LifeScript, an online health information company based in Mission Viejo, California.
About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound chemotherapeutic compound (ABRAXANE), which is based on the company's proprietary tumor targeting technology known as the nab(TM) platform. The first FDA approved product to use this nab(TM) platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.